Upcoming Webinar: Unifying Revascularization Guidelines Across Continents and Specialties

Saturday, 18 January 2025 Time: 10:00 a.m. CST (UTC-6) / 4:00 p.m. GMT (UTC+0).

This unique CTSNet webinar features Dr. Faisal Bakaeen, Professor of Surgery at the Cleveland Clinic Lerner College of Medicine, leading a transatlantic panel of cardiologists and cardiac surgeons discussing the 2024 ESC guidelines for managing chronic coronary syndromes (CCS) and their impact on patient care in both Europe and the United States. The panel includes cardiothoracic surgeons Thorsten Doenst and Dawn Hui, and cardiologists Elmir Omerovic and Michael Farkouh. 

Register for Webinar

The updated ESC guidelines provide a framework for diagnosing and treating suspected and confirmed cases of CCS. They emphasize using a risk factor-weighted model to better estimate the likelihood of obstructive coronary artery disease (CAD), which more accurately classifies patients into low-risk categories where further testing might not be needed. They offer detailed recommendations for anti-anginal medications, therapies to prevent events, adherence strategies and the selection of revascularization techniques based on recent research, and more. 

Time Zone Conversion

Panelists

• Dawn Hui, MD, Professor, Vice Chair of Quality and Research, University of Texas Health, Long School of Medicine, San Antonio, TX, USA
• Michael Farkouh, MD, Professor of Cardiology and Research Scientist, Smidt Heart Institute, Cedars Sinai, Los Angeles, CA, USA
• Torsten Doenst, MD, PhD, Head of Department of Cardiothoracic Surgery, University Hospital Jena, Germany
• Elmir Omerovic, MD, Professor, Principal Investigator, Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden

Moderator

• Faisal Bakaeen, MD, Professor of Surgery, Cleveland Clinic Lerner College of Medicine, USA 

Disclaimer

The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.